Biohaven announced plans to initiate pivotal clinical trials mid-2026 for its novel protein degrader therapies targeting IgA nephropathy and Graves' disease. The company expects topline results in the second half of 2026 from its epilepsy program using a selective Kv7 ion channel activator and from a Phase 2 obesity study with a myostatin-activin pathway inhibitor. Additional progress includes ongoing trials in early Parkinson's disease and advanced endometrial cancer, with no major safety issues reported. Biohaven reported a reduced net loss in Q1 2026 and maintains a strong cash position of approximately $352 million, positioning it well for upcoming milestones and continued development across its neuroscience, immunology, and oncology pipeline.
Silvaco and NVIDIA have teamed up to enhance semiconductor design and manufacturing by integrating NVIDIA's AI and accelerated computing with Silvaco's physics-based simulation technology. This collaboration aims to create high-fidelity digital twins...
Garden Finance has disabled its app following a security exploit that led to a loss of $450,000, as reported by the security firm Blockaid. This incident highlights ongoing risks in decentralized finance platforms. Users should be cautious and await ...
The FT Energy Income Partners Enhanced Income ETF (EIPI) remains a Buy due to strong structural demand in LNG exports and AI-driven power needs. The ETF uses a flexible option strategy, currently covering about 36%, to balance income generation with ...
On July 25, 2026, South Korean traders significantly increased Morpho (MORPHO) whale transactions, new wallet creations, and exchange outflows, reaching multi-month highs. This surge coincided with Upbit launching a Korean won trading pair for MORPHO...
Bitcoin climbed back above $65,000, rising about 1.2% amid a pause in US-Iran military actions, which eased geopolitical tensions and caused oil prices to fall nearly 5%. Ethereum outperformed Bitcoin with a 3% gain, signaling a potential altcoin ral...
